Authors
Latest:
KFF Webinar Explores Insurance Coverage of OpillLaurie Sobel, associate director for women’s health policy at KFF, moderated a panel discussion about the challenges associated with providing insurance coverage for the first FDA-approved oral contraceptive, Opill.
Latest:
Hemophilia Groups Protest BCBS of Tennessee Formulary ExclusionsThe patient groups say the insurer is cutting off access to important medications. The Tennessee Blues plans say many of the drugs that it excluded from coverage have zero utilization.
Latest:
Drugs and Older Age: An Increasingly Deadly CombinationTwo reports show that drug-related deaths are skyrocketing among people 65 years and older.
Latest:
Legal Challenges Likely for Drugs Listed for Medicare Price NegotiationExperts expect more lawsuits challenging CMS’s authority to negotiate drug prices for Medicare Part D.
Latest:
Oncology Drug Exkivity to be Withdrawn from U.S. MarketIn a confirmatory trial, Exkivity did not meet the primary endpoint in treating patients with non-small cell lung cancer with EGFR exon 20 mutations. It will remain available while Takeda works with the FDA on withdrawal timing.
Latest:
California Sues Drug Makers, PBMs Over Rising Prices for InsulinLawsuit accuses the companies of using unlawful, unfair, and deceptive practices.
Latest:
Antimicrobial stewardship programs-A review for the formulary decision-makerAntimicrobial stewardship programs are being implemented in a variety of settings to assist with the challenges associated with the management of infectious diseases. Here's a review of ASPs from the perspective of a formulary decision-maker.
Latest:
GlaxoSmithKline Halts RSV Vaccine Trials in Pregnant WomenThe setback for GlaxoSmithKline comes amid a multicompany race to develop a vaccine against respiratory syncytial virus infections.
Latest:
Up, Up and Not Going Away: Cancer Drug PricesEscalating costs are hitting patients hard. CMS price negotiation and the $2,000 cap on Part D out-of-pocket expenses should benefit many patients with Medicare coverage.
Latest:
Hyrimoz, a High-Concentration Humira Biosimilar, Approved by FDASandoz will now launch both high-concentration and low-concentration versions of Hyrimoz (adalimumab-adaz) in July.
Latest:
Second mRNA COVID-19 Vaccine in Primary Series Can Be Extended to 8 Weeks for Some IndividualsThis guidance discusses that individuals 12 years and older can receive the second dose of the Pfizer-BioNTech vaccine 3-8 weeks after the first. Additionally, the interval for those 18 years and older for Moderna is 4-8 weeks.
Latest:
Analysis: Farxiga is a High-Value Medication for Patients with Heart FailureThe recent study also found that Jardiance for patients with heart failure with preserved ejection fraction could be cost-effective if discounted by 29%.
Latest:
IRA Impact: Lowered Patient Costs, but Also Higher Utilization Management?Once Medicare’s negotiated price for prescription drugs goes into effect, payers have more of an incentive to steer patients to lower-cost alternatives.
Latest:
Study: One-Third of ACOs Use Digital Health Tools for Opioid Use DisorderAccountable care organizations (ACOs) use digital health to complement traditional resources.
Latest:
Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment DecisionsThe reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Latest:
Long-term Study Shows Gardasil 9 Effective Against HPV-Related CancersIn a 10-year, follow-up study in patients vaccinated with Gardasil 9, no cases of HPV-related cancers or genital warts were seen.
Latest:
Antimicrobial stewardship programs-A review for the formulary decision-makerAntimicrobial stewardship programs are being implemented in a variety of settings to assist with the challenges associated with the management of infectious diseases. Here's a review of ASPs from the perspective of a formulary decision-maker.
Latest:
Study: Medicaid Coverage Uneven for Gene TherapiesRecent study finds that Medicaid coverage for some of the first gene and cell therapies was at times delayed and not consistent with federal requirements.
Latest:
ASCO Abstract Highlights Growing Comfortability with Trastuzumab BiosimilarsThis abstract at the American Society of Clinical Oncology (ASCO 2023) looked at the growing utilization of trastuzumab biosimilars over time in India.
Latest:
Report: Medical Costs to Rise 7% Next YearThe increase is expected to be somewhat offset by the impact of biosimilars coming to market and more care being provided in outpatient settings.
Latest:
Class Action Lawsuit Filed Against CVS Caremark to Recoup DIR FeesThe class action lawsuit against CVS Health, Caremark, and Aetna was announced earlier today.
Latest:
Study: Coverage Restrictions One Reason for Lower Biosimilar AdoptionBiosimilars have the potential to lower costs, but the adoption has been slower than expected, a recent study finds.
Latest:
Prime Therapeutics Names Mostafa Kamal President and CEOThe Magellan Rx Management CEO is replacing Ken Paulus, who has held the top job at Prime since May 2019.
Latest:
Pfizer Tornado Plant Damage Not Affecting Penicillin SupplyThe supply of fentanyl, epinephrine injection, and heparin, however, have been impacted by the July 19 tornado at Pfizer's North Carolina facility.
Latest:
Overactive bladder drug not linked to CV eventsPatients with overactive bladder taking this OAB drug did not experience an excess risk of CV events compared with other treatments.
Latest:
FDA reviewing safety of Parkinson’s drugFDA is re-examining the safety of a breakthrough Parkinson’s disease drug after reports of hundreds of deaths.
Latest:
Wide geographic differences exist in treating diabetesA large-scale observational study led by Columbia University researchers may offer new approach to studying diverse patient groups.
Latest:
Popular insulin meets target in real-world studyNovo Nordisk’s DEVOTE study reveals interesting findings.
